Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 6/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988449 | 0.91 | BRAF (0.40) | MEN1KMT2ATP53GHSRBRAF | |
| SCHEMBL2980490 | 0.90 | BRAF (0.40) | MEN1KMT2AGHSRBRAFCYP11B1 | |
| SCHEMBL2980604 | 0.88 | BRAF (0.40) | MEN1KMT2ATP53GHSRBRAF | |
| SCHEMBL5147375 | 0.80 | BRAF (0.41) | BRAFHPGDSHTR2ARAF1 | |
| SCHEMBL2982070 | 0.80 | BRAF (0.46) | KMT2ABRAFRAF1MAPTPOLB | |
| SCHEMBL2983808 | 0.79 | BRAF (0.47) | KMT2ABRAFRAF1MAPTPOLB | |
| SCHEMBL2983705 | 0.79 | BRAF (0.47) | KMT2ABRAFRAF1MAPTPOLB | |
| SCHEMBL2988603 | 0.79 | BRAF (0.47) | KMT2ABRAFRAF1MAPTPOLB | |
| SCHEMBL2975806 | 0.79 | BRAF (0.47) | KMT2ABRAFRAF1MAPTPOLB | |
| SCHEMBL2988386 | 0.78 | SCN9A (0.44) | BRAFHPGDSRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | MEN1 3920/4885KMT2A 1112/4885TP53 98/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | MEN1 3920/4885KMT2A 1112/4885TP53 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.